FY2026 Earnings Estimate for BMY Issued By Erste Group Bank

Key Points

• Erste Group Bank raised Bristol Myers Squibb’s FY2026 EPS estimate to $6.96 from $6.34, matching the current consensus; its FY2027 forecast is $6.51 per share.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $2.04 EPS versus $1.60 consensus and $12.97 billion in revenue, up 5.7% year over year. Management’s FY2026 guidance is $6.75–$7.00 EPS.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and $66.06 average price target, while investors receive a $0.63 quarterly dividend yielding approximately 3.9%; patent expirations and generic competition remain key risks.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Erste Group Bank increased their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a report issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $6.96 per share for the year, up from their previous forecast of $6.34. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.96 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb's FY2027 earnings at $6.51 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. During the same period in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Several other brokerages have also recently issued reports on BMY. Citigroup reaffirmed a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target for the company in a report on Wednesday, August 5th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $64.75 on Tuesday. The company has a market capitalization of $132.27 billion, a PE ratio of 14.26, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.10. The company has a 50-day simple moving average of $58.91 and a 200-day simple moving average of $58.74. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

Institutional Investors Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC grew its stake in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after buying an additional 2,786 shares during the last quarter. United Bank increased its position in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock worth $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP bought a new stake in Bristol Myers Squibb in the second quarter valued at $221,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter valued at $405,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Major Houston manufacturing investment: BMY plans to invest approximately $2.3 billion in a roughly 600,000-square-foot manufacturing campus at Generation Park in Houston. The facility is expected to create nearly 500 permanent jobs and approximately 2,000 construction positions. The project expands domestic production capacity and is part of the company’s previously announced $40 billion U.S. investment commitment, supporting the company’s long-term operating and supply-chain strategy. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Positive Sentiment: Broker sentiment remains constructive: Brokerages currently assign BMY an average recommendation of “Moderate Buy,” suggesting analysts generally view the stock favorably despite some concerns about future growth and competition. Bristol Myers Squibb Receives Average Recommendation of Moderate Buy
• Neutral Sentiment: Recent performance has improved, but valuation requires caution: BMY has rallied about 16% over the past three months, supported by its growth portfolio and pipeline. Analysts say the momentum is encouraging, but the stock’s recent advance may limit near-term upside. BMY Rallies 16.2% in Three Months
• Negative Sentiment: Generic competition remains an overhang: While BMY’s pipeline and portfolio support the longer-term outlook, upcoming patent losses and generic competition could pressure revenue and earnings, making investors more cautious after the recent share-price gains. BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.